IL34537A - Piperidine derivatives and processes for the preparation thereof - Google Patents

Piperidine derivatives and processes for the preparation thereof

Info

Publication number
IL34537A
IL34537A IL34537A IL3453770A IL34537A IL 34537 A IL34537 A IL 34537A IL 34537 A IL34537 A IL 34537A IL 3453770 A IL3453770 A IL 3453770A IL 34537 A IL34537 A IL 34537A
Authority
IL
Israel
Prior art keywords
methanol
ketone
pyridyl
alkoxyphenyl
preparation
Prior art date
Application number
IL34537A
Other versions
IL34537A0 (en
Original Assignee
Minnesota 3M Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota 3M Lab Ltd filed Critical Minnesota 3M Lab Ltd
Publication of IL34537A0 publication Critical patent/IL34537A0/en
Publication of IL34537A publication Critical patent/IL34537A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/02—Preparation by ring-closure or hydrogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Description

Fiperldine derivatives and processes for the preparation thereof IHIESOTA 3M LABORATORIES LIMITED a- (HYDROXY AND ALKOXY SUBSTITUTED)PHENYL- -( 2-PIPERID«iYL)- METHANOLS AND PROCESSES FOR THE PREPARATION THEREOF This invention relates to substituted a-phenyl-a- (2-piperid4ftyl)methanols , to processes for the preparation thereof and to the use of said compounds and compositions containing them as bronchodilators .
The chemical compounds of the invention have the formula λ or wherein R is hydrogen or lower alkyl; R is hydrogen/ hy- 2 droxy -k-owor alkec-y; and R is hydrogen, lower alkyl, or ■phenyl, phenyl-lower alkyl,/diphenyl-lower alkyl, pheno¾y-•l-owe-p- alkyl -o^— lowo¾*-&i-ky3. Preferred compounds of the invention are those wherein the phenyl ring is substituted by at least two hydroxy groups in either the 3 and 5 positions or the 3 and 4 positions.
Process I of the invention comprises condensing a poly-lower alkoxy substituted benzaldehyde with picolinic acid or a lower alkyl-substituted picolinic acid to form an a- (poly-lower alkoxyphenyl )-a-(2-pyrid¾nyl)methanol or a- (poly-lower alkoxyphenyl)- (lower alkyl-substituted)-a- (2-pyridinyl )methanol intermediate, oxidizing said intermediate to form a (poly-lower alkoxyphenyl) 2-pyridylketone or (poly-lower alkoxyphenyl) (lower alkyl-substituted-2-pyridyl )-ketone intermediate, dealkylating to form the corresponding (poly-hydroxyphenyl) (2-pyridyl)ketone or (polyhydroxy-phenyl) (lower alkyl-substituted-2-pyridyl )ketone intermedl- ate which is hydrogenated to give the a- (polyhydroxyphenyl )-a-(2-piperidi«yl)methanol or a- (polyhydroxyphenyl)- (lower alkyl-substituted)-a- (2-piperidtnyl )methanol final product.
Process II of the invention comprises treating a lower alkoxy-substituted p-benzyloxybenzaldehyde (or di- or tri-alkoxy-substituted benzaldehyde ) with a 2-pyridyl- or lower alkyl-substituted-2-pyridyllithium reagent to form an a- ( lower alkoxy-p-benzyloxyphenyl )-a- ( 2-pyridtriyl )methanol or a-(lower alkoxy-p-benzyloxyphenyl)- (lower alkyl-substitu-ted)-a- (2-pyridittyl )methanol intermediate, removing the benzyl protecting group from said intermediate by hydrogen-ation in the presence of e.g. palladium catalyst to form an a-(lower alkoxy-p-hydroxyphenyl)-a- (2-pyridi»yl)methanol or a-(lower alkoxy-p-hydroxyphenyl)-(lower alkyl-substituted)- -(2-pyrid4»yl)methanol intermediate which is hydrogenated to form the ct-(lower alkoxy-p-hydroxyphenyl )-a- (2-piperi-diftyl )methanol or ot-(lower alkoxy-p-hydroxyphenyl)- (lower alkyl-substituted)-ct-(2-piperidi«yl)methanol final product.
Process III of the invention comprises condensing a (poly-lower alkoxyphenyl ) (6-methyl-2-pyridyl )-ketone and 1 , 3-propanediol in the presence of p-toluenesulfonic acid catalyst to form a 2- (poly-lower alkoxyphenyl )-2- (6-methyl- 2-pyridyl )-l, 3-dioxane intermediate, C-benzylating said intermediate through treatment with phenyllithium followed by benzyl chloride to form a mixture of the 2- (poly-lower alkoxyphenyl )-2- ( 6-phenethyl-2-pyridyl )-l , 3-dioxane and 2-(poly-lower alkoxyphenyl )-2-(6-dibenzylmethyl-2-pyridyl )-l, 3-dioxane intermediate, demethylating and hydrolytically cleaving the dioxane ring to form the (poly-hydroxyphenyl) (6-phenethyl-2-pyridyl)ketone and (poly-hydroxyphenyl) (6- - - dibenzylmethyl-2-pyridyl )ketone intermediates which are in turn hydrogenated to yield a separable mixture of the ct- (poly-hydroxyphenyl )-ot- (6-phenethyl-2-plperidi»yl )methanol and a- (poly- hydroxyphenyl )-a- ( 6-dibenzylmethyl-2-piperid£--«yl )methanol final products.
As used throughout this application the term "lower alkyl" embraces both straight and branched chain al-kyl radicals containing from 1 to 6 carbon atoms and cyclo-alkyl radicals containing from 3 to 6 carbon atoms, for ex-ample, but without limitation, methyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl, n-amyl, sec-amyl, n-hexyl, 2-ethylbutyl, 2 , 3-dimethylbutyl , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like; and the term "lower alkoxy" embraces both straight and branched chain alkoxy radicals containing from 1 to 6 carbon atoms, for example, but without limitation, methoxy, ethoxy, n-propoxy, isopro-poxy, n-butoxy, tert-butoxy, n-amyloxy, sec-amyloxy, n-hexyloxy, 2-ethylbutoxy , 2 , 3-dimethylbutoxy , and the like.
The compounds of this invention, in the form of their acid-addition salts, are solid crystalline materials.
The compounds of this invention have significant pharmacological activity as bronchdilator agents. The compounds of the present invention have been found to possess bronchodilator activity that is equivalent to, or better than, that possessed by the known bronchodilator agent aminophylline when evaluated, in vivo in the guinea pig and in vitro in an isolated tissue bath employing guinea pig tracheal tissue, at doses and concentrations, respectively, comparable to those of the aminophylline standards, both of these methods being recognized and accepted in the art of pharmacology for the evaluation of bronchodilator activity.
The starting materials for carrying out Process I of the invention are picolinic acid or a lower alkyl-substi-tuted picolinic acid, and a poly-lower alkoxy-substituted benzaldehyde. a-Picolinic acid and lower alkyl-substituted a-picolinic acids are conveniently prepared by the oxidation of a-picoline and polyalkylpyridines with potassium permanganate. Poly-lower alkoxy benzaldehydes are conveniently prepared by the reduction of the corresponding acid chlorides by the Rosemund procedure (Ber. 5,1:585 (1918)) or by lithium tri-t-butoxyaluminohydride , or by the oxidation of the corresponding benzyl alcohols, for example with manganese dioxide. Among the lower alkyl-substituted picolinic acids that may be used as a starting material, but without limita-tion, are 6-methylpicolinic acid, 5-ethylpicolinic acid, 4-n-propylpicolinic acid and 3-methylpicolinic acid; and among the poly-lower alkoxy-substituted benzaldehydes that may be used, but without limitation, are 2 , 3-dimethoxybenzaldehyde , 2 , -diethoxybenzaldehyde , 3 , 4-dimethoxybenzaldehyde , 2,4,6-trimethoxybenzaldehyde , 2 , 3 ,4-triethoxybenzaldehyde , 3,4,5-trimethoxybenzaldehyde and the like.
In carrying out Process I, the picolinic acid or lower alkyl-substituted picolinic acid and an appropriate poly-lower alkoxy-substituted benzaldehyde are condensed to form an a- (poly-lower alkoxyphenyl)-a-(2-pyrid£«yl)methanol wherein the substitution on the phenyl and pyridine rings corresponds to that in the starting materials. The condensation reaction is carried out in the presence of an inert solvent medium; such as p-cymene, nitrobenzene, or anisole; and at a temperature above l40° C. but preferably at the reflux temperature of the solvent used. The product of the reaction is then recovered by conventional procedures of isolation and crystallization.
The a- (poly-lower alkoxyphenyl)-a-(2-pyridtnyl)-methanol intermediate thus formed is then treated with a strong oxidizing agent such as, for example, potassium permanganate, dimethyl sulfoxide-acetic anhydride or dry air, and the like, to form the corresponding (poly-lower alkoxy-phenyl) (2-pyridyl)ketone. The crude alcohol can be oxi-dized without purification. The oxidation reaction may be carried out, when the oxidizing agent is potassium permanganate, in an aqueous solvent medium and at a temperature of up to 80° C. The product is recovered by conventional methods of isolation and purification, and then dealkylated by treatment, perferably, with hydrobromic acid to form a (polyhydroxyphenyl) (2-pyridyl )ketone . The dealkylation is accomplished by heating a solution of the ketone in constant boiling hydrobromic acid under reflux.
In the final step of the reaction sequence, the (polyhydroxyphenyl) (2-pyridyl )ketone is hydrogenated in the presence of a catalyst, e.g. Adams platinum catalyst or platinum on a charcoal support. The hydrogenatlon is carried out in the presence of an inert organic solvent, e.g. methanol, ethanol or acetic acid, and the like, at atmos-pheric pressure and a temperature of 20-60° C. The a- (polyhydroxyphenyl)-a-(2-piperid£«yl)methanol final product is recovered by conventional procedures for isolation and purification.
The starting materials for carrying out Process II of the invention are 2-pyridyllithium or lower alkyl- substituted 2-pyridyllithium, which may be prepared by treatment of 2-chloro- or 2-bromopyridine or a lower alkyl-substituted 2-chloro- or 2-bromopyridine in ether solution with freshly cut metallic lithium, and ¾-benzyloxy-3-methoxy benzaldehyde (or other alkoxy-substituted benzalde-hydes), which may be prepared from vanillin by refluxing with benzylchloride .
In carrying out the above-depicted reaction sequence, the 4-benzyloxy-3-methoxybenzaldehyde in an anhydrous inert organic solvent, e.g., anhydrous ether, is slowly added, at a temperature of from about 0° to -20° C, to a solution of 2-pyridyllithium or lower alkyl-substituted 2-pyridyllithium in an anhydrous inert organic solvent, e.g. anhydrous ether, also at a temperature of from about 0° to -20° C, and the resulting mixture allowed to warm to room temperature. The a- (lower alkoxy-p-benzyloxyphenyl)-a-(2-pyridiftyl)methanol or a-(lower alkoxy-p-benzyloxyphenyl )-(lower alkyl-substituted )-a-(2-pyridi«yl)methanol intermediate forms upon treatment of the reaction mixture with a mineral acid, e.g. hydrochloric acid, and is recovered by conventional techniques of separation and crystallization.
The benzyl protecting group is removed from the intermediate thus formed by hydrogenation in an inert organic solvent, e.g. methanol, in the presence of a pre-reduced palladium or palladium on charcoal catalyst at room temperature and atmospheric pressure. The a- (lower alkoxy-p-hydroxyphenyl)-a-(2-pyridi«-yl)methanol or -(lower alkoxy-p-hydroxyphenyl)- (lower alkyl-substituted)-a- (2-pyridi«yl)-methanol intermediate thus formed is recovered by conven-tional procedures of isolation and purification, and then converted to the corresponding a- (lower alkoxy-p-hydroxy-phenyl )-a- (2-piperidi»yl )methanol or a- (lower alkoxy-p-hydroxyphenyl )- (lower alkyl-substituted )-a-(2-piperid_tnyl )-methanol final product by oxidation first and then hydrogen-ation in the presence of catalyst as described above in the description of Process I of the invention. The final products are recovered by conventional methods of isolation and purification.
The starting material for carrying out Process III of the invention is a (poly-lower alkoxyphenyl) (6-methyl- 2-pyridyl)ketone which is prepared as described in the foregoing description of Process I of the invention.
In carrying out the reaction sequence, the substi-tuted-2-pyridylketone starting material is condensed with 1,3-propanediol in an inert organic solvent, e.g. toluene, in the presence of p-toluenesulfonic acid catalyst at the reflux temperature of the solvent used to form a 2- (poly lower-alkoxypheny1)-2- (6-methyl-2-pyridyl)-l, 3-dioxane intermediate .
Treatment of this intermediate, first with phenyl-lithium reagent and then benzyl chloride in an anhydrous inert organic solvent, e.g. tetrahydrofuran, at reflux temperature and under nitrogen, yields a mixture of 2- (poly-lower alkoxyphenyl )-2- ( 6-phenethyl-2-pyridyl )-l , 3-dioxane and 2-(l-poly-lower alkoxyphenyl )-2-(6-dibenzylmethyl-2-pyridyl)-l , 3-dioxane intermediates, which are separated and recovered by conventional methods of isolation and purification.
The phenethyl- and dibenzylmethyl-substituted in-termediates, thus obtained, are demethylated with simultane- ous opening of the dioxane ring to ketone formation, through treatment at reflux temperature with hydrobromic acid to yield the (polyhydroxyphenyl) (6-phenethyl-2-pyridyl )ketone and (polyhydroxyphenyl) (6-dibenzylmethyl-2-pyridyl)ketone intermediates which, after being recovered by conventional methods of isolation and purification, are converted to the a- (polyhydroxypheny1 )-a- ( 6-phenethyl-2-piperidi«yl )methanol and a- (polyhydroxyphenyl )-a- (6-dibenzylmethyl-2-piperidi«yl )-methanol final products by hydrogenation in the presence of catalyst as in the foregoing described Process I.
The compounds of this invention can, if desired, be converted into their pharmaceutically acceptable acid-addition and quaternary ammonium salts. Salts which may be formed comprise, for example, salts with inorganic acids, such as the hydrochloride, hydrobromide , hydroiodide, sulfate, phosphate or the like. They may also comprise salts with organic acids, including monobasic acids such as the acetate or the propionate, and especially those with hydroxy organic acids and dibasic acids, such as citrate, tartrate, malate and maleate. Pharmaceutically, the salt will not be substantially more toxic than the compound itself and is capable of being incorporated into conventional liquid or solid pharmaceutical media. Among the useful quaternary ammonium salts are those formed by such alkyl halides as methyl iodide, n-hexylbromide and the like. Such pharmaceutically useful acid-addition and quaternary ammonium salts are the full equivalents of the bases from which they are derived and are included within the scope of this invention.
The compounds of this invention, either as free bases or in the form of a pharmaceutically acceptable acid- addition or quaternary ammonium salt, can be combined with conventional pharmaceutical diluents and carriers to form such dosage forms as tablets, suspensions, solutions, suppositories and the like.
The individual unit dosage and frequency of administration is determined, not only by the nature and severity of the condition for which the subject seeks relief, but in addition upon age, weight, and species of subject, its underlying physical condition and the route of administra-tion. It will, accordingly, be within the judgment and skill of the practitioner administering the drug to determine the exact amount to be administered so as to be nontoxic, yet pharmaceutically effective in promoting broncho-dilation.
The following examples illustrate the preparation of the compounds of the present invention.
Example 1 (Process I) (a) a- ( 3. -DIMETHOXYPHENYL)-a- (2-PYRIDiHYL)METHANOL Picolinic acid (10 g.) was added over a period of three hours to a boiling solution of 3 , 4-dimethoxybenzalde-hyde (50 g.) in p-cymene (50 ml,). Heating was continued for three hours after the addition, and the reaction then allowed to cool. The cooled reaction mixture was extracted twice with 2N hydrochloric acid (total of 100 ml.). The combined acid extract was washed with ether (100 ml.), made basic with ammonia solution and then extracted four times with ether (total of 200 ml.). The combined ether extracts were concentrated to dryness to yield an oil which, from a solution of acetone-petroleum ether (b.p. 60-80° C), yielded a-(3,^-dimethoxyphenyl)-a-(2-pyridi*iyl)methanol, m.p. 93-95° C. Ether as used herein refers to diethyl ether, (b) ( 3 , -DIMETHOXYPHE YL) ( 2-PYRIDYL)KETONE a- ( 354-Dimethoxyphenyl )- - ( 2-pyridijayl )methanoi (10 g.), was suspended with stirring in water (200 ml.) and then warmed to 10° C. Potassium permanganate (^.7 g») was then added portionwise as the pink coloration was discharged. Excess permanganate was destroyed by the addition of ethanol and the manganese dioxide removed by filtration. The filter cake was extracted three times with boiling industrial methylated spirit (total of 300 ml.) and the filtrate then concentrated under reduced pressure until crystallization commenced. The white needles were collected by filtration, washed with water, and dried in vacuo to give (3 ,¾-dimeth-oxyphenyl) (2-pyridyl)ketone, m.p. 93-9^° C. (c) (3,4-DIHYDROXYPHENYL) (2-PYRIDYL) KETONE HYDROBROMIDE (3,4-Dimethoxyphenyl) (2-pyridyl)ketone (10 g.) was dissolved in constant boiling hydrobromic acid (100 ml.) and heated under reflux for three hours. The dark amber reaction solution was concentrated under reduced pressure and industrial methylated spirit was evaporated from the residue several times to remove the last traces of water. Crystallization from methanol (300 ml.) and ethyl acetate yielded (3,4-dihydroxyphenyl) (2-pyridyl)ketone hydrobromide , m.p. 225-226° C. (d) erythro- - ( 3 , -DIHYDROXYPHENYL )-a- (2-PIPERID¾YL)- METHANOL HYDROBROMIDE (3,^-Dihydroxyphenyl ) (2-pyridyl)ketone hydrobromide (20 g. ) in methanol (600 ml.) was hydrogenated at room temperature and at atmospheric pressure in the presence of Adams platinum catalyst (5 g»). After theoretical consump- - - tion of hydrogen had taken place, the catalyst and solvent were removed to give a syrup which solidified on trituration with ethyl acetate (250 ml.) and methanol (30 ml.) The solid was collected by filtration, washed with ethyl acetate/methanol (8:1, 50 ml.) and dried In vacuo to yield erythro-ot- (3 ,4-dihydroxyphenyl)-q- (2-piperidfaayl )-methanol hydrobromide, m.p. 220° C. (dec).
Analysis : Calculated for C12Hl8 03Br: C,47.4; H,6.0; N,4.6; Br, 26.3 Found: C,47.5; H.6.1; N,4.6; Br, 26.1.
Using the general method described in Example 1, the following compounds are made : Example 2 Starting with 6-methyl-picolinic acid and 3,4-di-methoxybenzaldehyde , compounds a, b, c and d are successively obtained. (a) a- ( 3 ,4-Dimethoxyphenyl )-a- ( 6-meth l-2-pyrid-hr 1 )metha-nol, m.p. 99-90° C. (b) (3,4-Dimethoxyphenyl) (6-methyl-2-pyridyl)ketone, m.p. 84-86° C. (c) (3,4-Dihydroxyphenyl) (6-methyl-2-pyridyl )ketone hydro-bromide, m.p. 224° C. (d.). (d ) a- ( 3 , 4-Dihydroxypheny 1 ) -a- ( 6-methyl-2-piperid4nyl )-methanol hydrobromide, m.p. 216° C. (d.).
Example 3 Starting with picolinic acid and 3,4 ,5-trimethoxy-benzaldehyde , compounds a, b, c and d are successively obtained. (a) a- ( 3 , , 5-Trimethoxyphenyl )-a- ( 2-pyridteyl )methanol , (b) (3, ,5-Trimethoxyphenyl) (2-pyridyl )ketone , m.p. 111-112° C. (c) ( 3a ^ , 5-Trihydroxyphenyl) (2-pyridyl )ketone hydrobro-mide, m.p. 2 0° C. (d.). (d) erythro-g- ( 3 » » 5-Trihydroxypheny1 )-g- ( 2-piperldir»y1 )-methanol hydrobromide , m.p. 130-140° C.
Example 4 (Process II) (a) ct- ( 4-BENZYLOXY-3-METHOXYPHENYL)-a- ( 2-PYRID^JYL)METHANOL Small pieces of lithium (12.7 g.) were suspended in dry ether (250 ml.) under nitrogen and n-butyl bromide (123 g. ) in dry ether (100 ml.) was added over a period of 0.5 hour at -5° to 0° C. The mixture was stirred for 2.5 hours at this temperature and then cooled to -20° C. when 2-bromopyridine (95 g.) in dry ether (50 ml.) was added drop-wise. After the addition, the mixture was stirred for 15 minutes and then 4-benzyloxy-3-methoxybenzaldehyde (145 g.) in dry ether (1.5 liters) was added over a one hour period at -20° C. On completion of the addition, the reaction mixture was allowed to attain room temperature over a period of 1.5 hours. Treatment of the mixture with 3N hydrochloric acid afforded crude product which separated at the interface between the phases and which was collected by filtration and dried in vacuo over phosphorus pentoxide. Concentration of the ethereal layer gave a dark brown oil which on tritura-tion with the acid layer afforded a further quantity of crude a- (4-benzyloxy-3-methoxy)- - (2-pyridi«yl )methanol which was recrystallized from ethanol, m.p. 124-125° C, (b) a- ( 4-HYDROXY-3-METHOXYPHENYL)-a- ( 2-PYRIDiMYL )METHANOL A solution of a-(4-benzyloxy-3-methoxyphenyl)-a-(2-pyrid4«yl)methanol (80 G.) in methanol (1,5 liters) was - - shaken with hydrogen in the presence of pre-reduced palladium on charcoal catalyst (10%, 40 g.) at room temperature and atmospheric pressure until the theoretical consumption of gas had taken place. Removal of the catalyst and concentra-tion of the solution to a volume of about 250 ml., after storage at 0° C, yielded a-(4-hydroxy-3-methoxy )-a-(2-pyr-id£»yl)methanol, m.p. 136-137° C. Two further crops of product were obtained by concentration of the mother liquors. An analytical sample had m.p. 137° C.
Analysis: Calculated for C^H^NO^: C, 67.5; H, 5.7; N, 6.1 Found: C, 67.35; H, 5.5; N, 6.0. (c ) erythro-ct- ( 4-HYDROXY-3- ETHOXYPHENYL)-a- (2-PIPERIDfWYL)- METHANOL HYDROCHLORIDE A solution of a-(4-hydroxy-3-methoxyphenyl)-a-(2-pyridtnyDmethanol (25.5 g.) in methanol (200 ml.) and 5N hydrochloric acid (23 ml.) was hydrogenated at room temperature and atmospheric pressure in the presence of Adams platinum catalyst (3 g.). After hydrogen (3 mole) had been con-sumed, the catalyst and solvent were removed to give a solid residue. Recrystallization of this material from a mixture of methanol and ether gave erythro-ot-( 4-hydroxy-3-methoxy-phenyl)-a-(2-piperidirrJl)methanol hydrochloride, m.p, 242-245° C.
Analysis: Calculated for C13H2()N03C1: C,57»0; H,7.4; N,5.1; CI,12.95 Pound: C,57.1; H,7.4; N.5.1; CI, 13.3.
Example 5 (Process III) (a) 2- ( 3 , 4-DIMETHOXYPHENYL)-2- ( 6-METHYL-2-PYRIDYL)-l , 3- DIOXANE ( 3 , 4-Dimethoxypheny1 ) ( 6-methyl-2-pyridyl )ketone (77.1 g. , 0.3 mole), p-toluenesulfonic acid (74.1 g., 0.39 mole) and 1 , 3-propanediol (22.8 ml., 0.315 mole) in toluene (600 ml.) were heated under reflux with stirring for 17 hours, the water evolved during the reaction being trapped by means of a Dean and Stark head. The cooled solution was neutralized with saturated sodium bicarbonate (500 ml.) and the phases separated. The organic layer was washed with saturated sodium bicarbonate solution and dried over magne-sium sulfate. Removal of the desiccant and solvent gave a solid residue which on recrystallization from a mixture of acetone and petroleum ether (b.p. 60-80° C.) yielded 2-(3,4-dimethoxyphenyl )-2- (6-methyl-2-pyridyl )-l, 3-dioxane , m. . 124-126° C. (b) 2-(3,4-DIMETHOXYPHENYL)-2-(6-PHENETHYL-2-PYRIDYL)-l,3- DIOXANE and 2- ( 3 , 4-DIMETHOXYPHENYL )-2- (6-DIBENZYLMETH- YL-2-PYRIDYL)-! , 3-DIOXANE Bromobenzene (8.66 ml.) in dry ether (20 ml.) was added over a period of 30 minutes to a stirred suspension of lithium shavings (1.0 g.) in dry ether (50 ml.) under a nitrogen atmosphere This rate of addition was sufficient to maintain the reaction at a gentle reflux. After the addition, the mixture was stirred for 1.5 hours and then 2- (3, 4-dimethoxyphenyl)-2-(6-methyl-2-pyridyl)-l, 3-dioxane (18.9 g.) dissolved in the minimum quantity of dry tetrahydrofuran was added. Benzyl chloride (8 g„) in dry tetrahydrofuran (10 ml.) was then added dropwise at such a rate that gentle boiling occurred, and the reaction was stirred for 0.5 hour after the addition. Lithium complexes were decomposed by the addition of saturated ammonium chloride solution and the phases were separated. The organic layer was diluted with ether (200 ml.) and extracted with 2N hydrochloric acid (2 x 100 ml.). The acid extract was washed with ether (100 ml.), basified with ammonia solution and the liberated basic products extracted into chloroform (2 x 60 ml.). Concentration of the dried extracts gave a syrup which was applied to a column of silica gel (30 x 4cm) and eluted with a mixture of chloroform/ethyl acetate (4:1). Twenty-four successive fractions (25 ml.) were collected and examined by thin layer chromatography. Three main components were detected in the reaction mixture, and the slowest moving compound had an identical mobility to that of the starting material. Fractions 1 to 13 were discarded since no product was detected. Fractions after 24 were discarded be-cause they contained increasing amounts of starting material. Fractions 14 to 16 and 17 and 18 gave crystalline material on trituration with ethanol which had identical infrared spectra (no carbonyl functions present). Recrystal-lization of this material from ethanol yielded 2-(3,4-di-methoxyphenyl )-2- (6-dibenzylmethyl-2-pyridyl )-l , 3-dioxane , m.p. 124° C.
Analysis : Calculated for C^H^NO^: C, 77.55; H, 6.7; N, 2.8 Found: C, 77.65; H, 6.8; N, 3.0.
Fractions 19 to 21 and 22 to 24 slowly crystallized and recrystallization from industria1 methylated spirit gave 2- ( 3 , -dimethoxyphenyl )-2- ( 6-phenylethyl-2-pyridyl)-l, 3-dioxane, m.p. 86-87° C.
Analysis : Calculated for C^H^NO^: C, 74.05; H, 6.7; N, 3.45 Found: C, 7^.1; H, 6.6; N, 3.6. (c) (3,4-DIHYDROXYPHENYL) (6-PHENETHYL-2-PYRIDYL)KETONE HYDROBROMIDE A solution of 2-(3,4-dimethoxyphenyl)-2-(6-pheny*--ethyl-2-pyridyl)-l,3-dioxane (3.5 go) in hydrobromic acid ( 8¾, 20 ml.) was heated under reflux for 20 hours. The solvent was removed under reduced pressure and industrial methylated spirit was evaporated several times from the residue which crystallized on trituration with ethyl acetate. Recrystallization from methanol-ethyl acetate yielded (3*4-dihydroxyphenyl) (6-phenylethyl-2-pyridyl )ketone hydrobro-mide, m.p, 181° C.
Analysis : Calculated for C20H"l8N03Br: C,60.0; H,4.5; N,3.5; Br, 20.0 Pound: C,60.2; H,¾.7; N.3.6; Br, 20.35. (d) ( 314-DIHYDROXYPHENYL) (6-DIBENZYLMETHYL-2-PYRIDYL)- KETONE A solution of 2- ( 3 , 4-dimethoxyphenyl )-2- (6-diben-zylmethyl-2-pyridyl)-l,3-dioxane (2.0 g.) in constant boil-ing hydrobromic acid (20 ml.) was heated under reflux for 16 hours. The free base was liberated with ammonia solution and extracted into ether (2 x 50 ml„). Removal of the solvent from the dried extracts gave a syrupy residue which on crystallization from ether-petroleum ether (b.p. 60-80° C.) yielded ( 3,M-dihydroxyphenyl) (6-dibenzylmethyl-2-pyridyl )-ketone, m.p. I l-1¾3° C. (e ) erythro- - ( 3 , 1-DIHYDR0XYPHE YL)-a- ( 6-PHENETHYL-2-PIPER- IDHBfL)METHANOL HYDROBROMIDE ( 3,^-Dihydroxyphenyl ) (6-phenylethyl-2-pyridyl)-ketone hydrobromide (2.0 g.) in methanol (100 ml.) was hy- drogenated in the presence of Adams platinum catalyst (0,2 g.) at atmospheric pressure and room temperature. After hydrogen (J mole) had been consumed, the catalyst and solvent were removed to give a syrup from which a sample (100 mgo) was removed for nuclear magnetic resonance spectroscopic analysis. The remainder was crystallized from a mixture of methanol-ethyl acetate to give erythro-ot- ( 3 » -di-hydroxyphenyl )-a- ( 6-phenylethyl-2-piperidi»yl )methanol hy-drobromide, m0p, 20*1° C„ Analysis : Calculated for C2()H26N03Br: C,58.8; H,6.4; N.3.4; Br, 19.6 Pound: C,5806; H,6.6; N,3.5; Br, 19.9. ( f) a- ( 3 , Ί-DIHYDROXYPHENYD-a- ( 6-DIBENZYLMETHYL-2-PIPERI- DgJYL)METHANOL A solution of (3,^-dihydroxyphenyl) (6-dibenzyl-methyl-2-pyridyl )ketone (1.2 g.) in methanol (100 ml.) and 5M hydrochloric acid (0,585 ml.) was hydrogenated in the presence of Adams platinum catalyst (0,3 g.) at room temperature and atmospheric pressure. After the theoretical quan-tity of hydrogen had been consumed, the catalyst and solvent were removed to give a syrup. The evaporation of ethyl acetate from the residue afforded a dry froth which was powdered under ether, collected by filtration and dried in vacuo . Yield, 1,22 g, Example 6 a-( 3 ,4-Dihydroxyphenyl )-a-2-piperid4R.yl methanol of Example 1 was tested for bronchodilator activity and the results compared with those obtained in the same test with aminophylline and isoprenaline (3,^-dihydroxy-a-[(isopropyl-amino)methyl]benzyl alcohol, an established bronchodilator - - agent also known as isoproterenol, (a) ISOLATED ORGANS The test compound had approximately the same relaxant activity as isoprenaline when tested on the isolated guinea pig trachael chain, and approximately 31,000 times the activity of aminophylline . (b) ANESTHETIZED ANIMALS The test compound inhibited histamine-induced broncho-spasm in the anesthetized artificially respired guinea pig. The test compound had approximately l/15th the activity of isoprenaline when administered intravenously, and approximately 2,000 times the activity of aminophylline. After oral administration the test compound was active at a dose of 10 mg/kg, while isoprenaline is active at 2.5 mg/kg. (c) CONSCIOUS ANIMALS The test compound reduced the severity of the anaphylactic reaction in sensitized guinea pigs challenged by inhalation of antigen.
The test compound had oral activity comparable to aminophylline at a dose of 25 mg/kg0 It had activity comparable to isoprenaline when injected intraperitoneally .
The test compound was administered as the hydro-bromide and isoprenaline as isoprenaline sulfate. - -

Claims (1)

  1. What we claim A compound of the formula 1 wherein R is hydrogen or lower R is hydrogen droxy and R is lower or alkyl and the cally acceptable and quaternary ammonium salts 3 3 3 3 3 dinyl Compounds according to any of claims 1 to ally as described in the specification and in Examples 1 to n A process for the preparation of of formula I Claim 1 which comprises condensing a lower benzaldehyde with picolinic acid or a lower picolinic acid in the presence of an inert organic solvent having a boiling point above to form an alkoxyphenyl oxidizing the alkoxyphenyl to form a alkoxyphenyl dealkylating the to form a and hydrogenating the in the presence of a catalyst to form an A process for the preparation of of formula I in Claim 1 which comprises treating a lower with or lower lithium in the presence of an anhydrous inert organic vent at a temperature of from to room temperature to form an removing the benzyl protecting group from said by hydrogenation in the presence of a palladium catalyst to form an methanol which is hydrogenated in the presence of a platinum catalyst to form the piperidiny1 A process for the preparation of and of I in Claim 1 phenyl prises condensing a pyridyl ketone and 1 in an inert organic vent at reflux temperature of the solvent and in the ence of acid catalyst to form a lower alkoxyphenyl benzylating said alkoxyphenyl by treatment with phenyllithium lowed by benzyl chloride to form and alkoxy ating and hydrolytically cleaving the dioxane ring of said compounds to form ketone and ketone which are hydrogenated in the presence of platinum catalyst to yield the and 12 Process for the preparation of compounds according to any of claims 1 to substantially as described in Examples 1 to Process for the preparation of compounds according to any of claims 1 to substantially as hereinbefore Process for preparing compounds of the formula wherein R is hydrogen or lower R is droxy and R is lower alkyl which comprises drogenating a compound of the formula wherein R and R are as defined above and B is or I HCOH in the presence of 22 For the AND insufficientOCRQuality
IL34537A 1969-05-20 1970-05-17 Piperidine derivatives and processes for the preparation thereof IL34537A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2563469 1969-05-20

Publications (2)

Publication Number Publication Date
IL34537A0 IL34537A0 (en) 1970-07-19
IL34537A true IL34537A (en) 1973-03-30

Family

ID=10230843

Family Applications (1)

Application Number Title Priority Date Filing Date
IL34537A IL34537A (en) 1969-05-20 1970-05-17 Piperidine derivatives and processes for the preparation thereof

Country Status (12)

Country Link
JP (1) JPS4920787B1 (en)
BE (1) BE750590A (en)
CH (1) CH541557A (en)
DE (1) DE2024049C3 (en)
DK (1) DK124027B (en)
FR (1) FR2051549B1 (en)
GB (1) GB1316424A (en)
IL (1) IL34537A (en)
NL (1) NL169314C (en)
NO (1) NO133448C (en)
SE (1) SE374366B (en)
ZA (1) ZA703208B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA960676A (en) * 1970-05-21 1975-01-07 Smith Kline And French Canada Ltd. 3-sulfonamido-4-hydroxyphenyl-2-piperidinylcarbinols
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
CA2083698C (en) * 1990-06-01 1997-11-04 Albert A. Carr (+)-alpha-(2,3-dimethoxyphenyl)-1- [2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569836A (en) *

Also Published As

Publication number Publication date
CH541557A (en) 1973-09-15
NL7007303A (en) 1970-11-24
DE2024049A1 (en) 1970-12-17
NL169314B (en) 1982-02-01
IL34537A0 (en) 1970-07-19
NO133448B (en) 1976-01-26
DE2024049C3 (en) 1978-07-20
DK124027B (en) 1972-09-04
SE374366B (en) 1975-03-03
JPS4920787B1 (en) 1974-05-27
GB1316424A (en) 1973-05-09
BE750590A (en) 1970-11-19
DE2024049B2 (en) 1977-11-24
ZA703208B (en) 1971-01-27
FR2051549A1 (en) 1971-04-09
FR2051549B1 (en) 1974-08-30
NL169314C (en) 1982-07-01
NO133448C (en) 1976-05-05

Similar Documents

Publication Publication Date Title
DE2204195C2 (en) 2-Hydroxymethyl-3-hydroxy 6- (1-hydroxy-2-aminoethyl) pyridines, processes for their preparation and pharmaceutical preparations containing the same
US3813404A (en) Tropane-2-carboxylates and derivatives
Williams et al. A Comparison of Methods for the Preparation of 2-and 4-Styrylpyridines1
JPS5989660A (en) 1-phenyl-2-piperidinoalkanol derivative
US4843074A (en) 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
US4338323A (en) Piperidylbenzimidazolinone derivatives
US3910934A (en) Process for the preparation of {60 -(hydroxy and alkoxy substituted)phenyl-{60 -(2-piperidinyl)-methanols
US3940404A (en) 2-Substituted phenyl-6-trifluoromethyl-4-pyridyl-carbinolamines
IL34537A (en) Piperidine derivatives and processes for the preparation thereof
US3941796A (en) α-(Hydroxy and alkoxy substituted)phenyl-α-(2-piperidinyl)-methanols
US3953463A (en) 2-Aryl-6-trifluoromethyl-4-pyridyl-carbinolamine antimalarials
Reitz et al. Dipole-stabilized carbanions: secondary (. alpha.-lithioalkyl) alkylamine synthetic equivalents from N, N-dialkyl-2, 2-diethylbutyramides
US2355659A (en) Piperidine derivatives and process for the manufacture of the same
US4049653A (en) Heterocyclic esters of alkylphenyl benzopyrans
Mashkovsky et al. Relationships between the chemical structure and pharmacological activity in a series of synthetic quinuclidine derivatives
CA1148163A (en) 4(or 3)-(3,4-dihydroxyphenyl)pyridines, their preparation and use as cardiotonics
JPH085863B2 (en) 14-Anisoylaconine and novel analgesic / anti-inflammatory agent containing the same
US4442106A (en) Quinoline derivatives, pharmaceutical compositions containing such compounds, and methods of treating cardiovascular conditions with them
US4443453A (en) Quinoline derivatives, pharmaceutical compositions containing such compounds, and methods for treating cardiovascular conditions with them
US4355045A (en) Anti-inflammatory 1-phenylethanolamine derivatives pharmaceutical compositions thereof and processes for their manufacture
US4113729A (en) 3-Phenoxymorphinans and derivatives thereof
US3923992A (en) Analgetic composition and method of use
Cohen et al. Antiplasmodial action and chemical constitution Part I. Cinchona alkaloidal derivatives and allied substances
KR850000126B1 (en) Method for preparing imidazole derivative
US5330983A (en) 14-O-p-chlorobenzoylaconine and analgesic/anti-inflammatory agent containing the same